Send to

Choose Destination
See comment in PubMed Commons below
Chin J Cancer Res. 2013 Jun;25(3):358-61. doi: 10.3978/j.issn.1000-9604.2013.06.09.

Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.

Author information

  • 1Department of Oncology, PLA Navy General Hospital, Beijing 100048, China.


Bevacizumab, an angiogenesis inhibitor, is a recombined humanized monoclonal antibody against vascular endothelial growth factor and a promising therapeutic option for angiosarcoma management. This is a case report and review of the literature using bevacizumab and combination chemotherapy for angiosarcoma. The understanding of the effectiveness of combined therapy of bevacizumab and chemotherapy agents is still limited. The benefits of bevacizumab treatment for angiosarcoma will need to be weighed against the risks of venous thromboembolism in this population.


Angiosarcoma; angiogenesis inhibitor; bevacizumab; chemotherapy; combination therapy

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for AME Publishing Company Icon for PubMed Central
    Loading ...
    Write to the Help Desk